Fish oil supplements in patients with chronic kidney disease - PubMed
5 hours ago
- #fish oil supplements
- #cardiovascular disease
- #chronic kidney disease
- Cardiovascular disease (CVD) is the main cause of increased morbidity and mortality in chronic kidney disease (CKD).
- Cardiovascular risk in CKD starts with atherosclerotic events and shifts to heart failure and sudden cardiac death later.
- Established therapies like lipid-lowering drugs offer limited benefit in dialysis patients, despite their high cardiovascular risk.
- Recent advances such as SGLT2 inhibitors and GLP1 receptor agonists improve outcomes in non-dialysis CKD but not in dialysis patients.
- Omega-3 polyunsaturated fatty acids (PUFAs) have pleiotropic effects including anti-inflammatory, anti-oxidative, anti-thrombotic, plaque stabilizing, and membrane modulating actions.
- The PISCES trial showed a 43% reduction in cardiovascular events with high-dose fish oil (1.6 g EPA + 0.8 g DHA daily) in 1228 hemodialysis patients over 3.5 years.
- Prior fish oil studies in CKD were small and inconclusive, highlighting the need for larger randomized trials to confirm efficacy.
- If validated, omega-3 PUFAs could represent a significant advance for improving cardiovascular outcomes in hemodialysis patients.